# Bristol-Myers Squibb Company (BMY) — Q1-2022 Earnings Results

**Report date:** 2022-04-29 (before market open)  
**Sector:** Health Care / Pharmaceuticals  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/BMY/earnings/Q1-2022

## Post-Earnings Brief

### Headline

Bristol Myers Squibb Beats on EPS, Stock Down 2.5%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.96 | N/A | +2.35% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management expressed confidence in their pipeline and future growth. However, they acknowledged challenges in the current market environment.

**Key quotes:**

> Management highlighted ongoing commitment to innovation in drug development.

> They emphasized the importance of maintaining strong operational performance.

### Guidance Changes

No guidance updates were provided during the earnings call.

### What It Means

Bristol Myers Squibb's earnings report showed a positive surprise on EPS, indicating better-than-expected profitability. However, the stock fell by 2.5% following the announcement, likely due to the lack of revenue details and guidance. Investors may be cautious given the uncertainties in the market and the absence of forward-looking statements from management.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/BMY/earnings/Q1-2022_